Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Depreciation & Amortization (CF) (2016 - 2021)

Phio Pharmaceuticals' Depreciation & Amortization (CF) history spans 10 years, with the latest figure at $20000.0 for Q4 2021.

  • For Q4 2021, Depreciation & Amortization (CF) rose 17.65% year-over-year to $20000.0; the TTM value through Dec 2021 reached $75000.0, up 4.17%, while the annual FY2025 figure was $3000.0, 50.0% up from the prior year.
  • Depreciation & Amortization (CF) reached $20000.0 in Q4 2021 per PHIO's latest filing, up from $19000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $22000.0 in Q4 2017 to a low of $11000.0 in Q1 2017.
  • Average Depreciation & Amortization (CF) over 5 years is $18250.0, with a median of $18000.0 recorded in 2019.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 83.33% in 2017, then decreased 25.0% in 2019.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $22000.0 in 2017, then fell by 9.09% to $20000.0 in 2018, then decreased by 20.0% to $16000.0 in 2019, then grew by 6.25% to $17000.0 in 2020, then grew by 17.65% to $20000.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Depreciation & Amortization (CF) are $20000.0 (Q4 2021), $19000.0 (Q3 2021), and $18000.0 (Q2 2021).